
Oncology NEWS International
- Oncology NEWS International Vol 5 No 7
- Volume 5
- Issue 7
New Company Joins With RPR To Develop Intrabody Technology
COLLEGEVILLE, Penn--Intra-immune Therapies, Inc., a new company formed by Dr. Wayne Marasco, of the Dana-Farber Cancer Institute, has joined the Rhône-Poulenc Rorer Gencell network to help accelerate the development of its innovate intrabody, or intracellular antibody, technology.
COLLEGEVILLE, Penn--Intra-immune Therapies, Inc., a new companyformed by Dr. Wayne Marasco, of the Dana-Farber Cancer Institute,has joined the Rhône-Poulenc Rorer Gencell network to helpaccelerate the development of its innovate intrabody, or intracellularantibody, technology.
An intrabody is an engineered human antibody that works insidea cell, offering the potential for blocking molecular changesthat can lead to dis-eases such as cancer.
Articles in this issue
almost 30 years ago
Princess Diana Helps Raise Over $1 Million for Cancer Researchalmost 30 years ago
Study Gives Terminal Patients Option: $18,000 or More Treatmentalmost 30 years ago
Proven: Colorectal Screening Cuts Deaths 50%almost 30 years ago
Virtual Colonoscopy Technique Feasible in Detecting Polypsalmost 30 years ago
Trimetrexate Appears Beneficial in Colorectal Canceralmost 30 years ago
FDA Liaison Program Answers Patients' Questions About Trialsalmost 30 years ago
More Insurers Covering ABMT, Despite Lack of Efficacy Dataalmost 30 years ago
CDC Says Teen Smoking Still Risingalmost 30 years ago
ThinPrep Pap Test Offers Improved Slide PreparationRelated Content


97 monarchE: Evaluation of Prognostic and Predictive Value of Ki-67 Index Pre- and Post-Neoadjuvant Chemotherapy and Changes Following NAC

98 A Phase 1/2 Trial of LY4064809, A Pan-Mutant-Selective PI3Kα Inhibitor in HR+/HER2− Advanced Breast Cancer, Updated Results From PIKALO-1





















































